Association of OCT-Derived Drusen Measurements with AMD-Associated Genotypic SNPs in the Amish Population

Venkata Ramana Murthy Chavali 1, Bruno Diniz 2,3, Jiayan Huang 4, Gui-Shuang Ying 4, Srinivas R. Sadda 2,5 and Dwight Stambolian 1,*

1 Department of Ophthalmology, University of Pennsylvania, 313B Stellar-Chance Labs, 422 Curie Blvd., Philadelphia, PA 19104, USA; E-Mail: vchavali@mail.med.upenn.edu
2 Doheny Eye Institute, Los Angeles, CA 90033, USA; E-Mails: bdinizlt@hotmail.com (B.D.); vassadda@gmail.com (S.R.S.)
3 Department of Ophthalmology, Universidade Federal de São Paulo, São Paulo 09920, Brazil
4 Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA; E-Mails: huangjiyan@gmail.com (J.H.); gsying@mail.med.upenn.edu (G.-S.Y.)
5 Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA

* Author to whom correspondence should be addressed; E-Mail: stamboli@mail.med.upenn.edu; Tel.: +1-215-898-0305; Fax: +1-215-573-6728.

Academic Editors: Lindsay Farrer and Margaret DeAngelis

Received: 23 December 2014 / Accepted: 13 January 2015 / Published: 12 February 2015

Abstract: Purpose: To investigate the association of optical coherence tomography (OCT)-derived drusen measures in Amish age-related macular degeneration (AMD) patients with known loci for macular degeneration. Methods: Members of the Old Order Amish community in Pennsylvania ages 50 and older were assessed for drusen area, volume and regions of retinal pigment epithelium (RPE) atrophy using a Cirrus High-Definition OCT. Measurements were obtained in the macula region within a central circle (CC) of 3 mm in diameter and a surrounding perifoveal ring (PR) of 3 to 5 mm in diameter using the Cirrus OCT RPE analysis software. Other demographic information, including age, gender and smoking status, were collected. Study subjects were further genotyped to determine their risk for the AMD-associated SNPs in the SYN3, LIPC, ARMS2, C3, CFB, CETP, CFI and CFH genes using TaqMan genotyping assays. The association of genotypes with OCT measures were assessed using linear trend p-values calculated from univariate and
multivariate generalized linear models. Results: 432 eyes were included in the analysis. Multivariate analysis (adjusted by age, gender and smoking status) confirmed the known significant association between AMD and macular drusen with the number of CFH risk alleles for the drusen area (the area increased 0.12 mm² for a risk allele increase, \( p < 0.01 \)), drusen volume (the volume increased 0.01 mm³ for a risk allele increase, \( p \leq 0.05 \)) and the area of RPE atrophy (the area increased 0.43 mm² for a risk allele increase, \( p = 0.003 \)). SYN3 risk allele G is significantly associated with larger area PR (the area increased 0.09 mm² for a risk allele increase, \( p = 0.03 \)) and larger drusen volume in the central circle (the volume increased 0.01 mm³ for a risk allele increase, \( p = 0.04 \)). Conclusion: Among the genotyped SNPs tested, the CFH risk genotype appears to play a major role in determining the drusen phenotype in the Amish AMD population.

**Keyword:** age-related macular degeneration; AMD; Older Order Amish; CFH; SYN3; OCT; drusen area; drusen volume; RPE atrophy; Cirrus HD-OCT

1. Introduction

Age-related macular degeneration (AMD) is a leading cause of vision loss and is influenced by genetic, environmental and dietary factors [1]. It is estimated that in the United States alone, the number of advanced AMD cases may reach up to three million by the year 2020 [2]. Clinical features of AMD include the death of photoreceptors and retinal pigment epithelium (RPE). Drusen are hallmark deposits associated with early AMD and considered to be a major risk factor for the progression of AMD [3–5]. The late stages of AMD are classically divided into two forms: non-neovascular (“dry”) AMD/atrophic AMD and neovascular (“wet”) AMD. Several studies have identified a variety of potential risk factors associated with AMD [6].

In recent years, significant advances have been made in our understanding of the genetic basis of AMD. Gene variants or single-nucleotide polymorphisms (SNPs) are routinely used to test the association with disease phenotypes. SNPs that increase risk or are protective have been identified for several complement-related genes: factor H (\( CFH \)) [7–10], the complement factor B region (\( CFB \)) [11,12], complement factor I [13], complement \( C3 \) [14,15] and the ARMS2/serine protease \( HTRA1 \) [16–19]. A variant in the hepatic lipase gene, \( LIPC \), was reported to decrease the risk of advanced AMD in a genome-wide association study (GWAS) [20,21]. Other genes in the HDL pathway and cholesterol transport, including CETP, are hypothesized to be involved in the etiology of AMD [22].

The risk of AMD progression has been positively correlated with total drusen area and the drusen size using fundus photography [23,24]. Color fundus photographs (CFPs) are the most widely-used method for the assessment of AMD. However, reliable quantitation of drusen using CFPs is challenging due to the macular background from RPE and choroidal pigmentation [25]. Furthermore, most published methods for grading CFPs for drusen feature a qualitative or semi-quantitative approach and are thus less sensitive to small changes in drusen number in early disease. Furthermore, as CFPs are two-dimensional, only the drusen area can be estimated, while drusen thickness and volume cannot be measured. We had earlier developed an automated drusen detection system for classifying age-related macular degeneration (AMD) from color
fundus photographs (CFPs) to overcome a few of these limitations [26]. More recently, optical coherence tomography (OCT) has been advocated as a potentially useful technique for in vivo cross-sectional imaging of drusen and quantitative evaluation of retinal structure. Development of higher speed and higher sensitivity spectral domain OCT systems (SD-OCT) has further enhanced our ability to obtain high resolution imaging of the RPE and drusen [27,28].

In the current study, we describe the correlation of OCT-derived measures of drusen and RPE atrophy in an elderly Amish population with SNP genotypes in the CFH, CFI, CFB, CETP, C3, ARMS2, LIPC and SYN3 genes.

2. Methods

2.1. Subjects

Amish individuals living in Lancaster County, Pennsylvania, with early AMD were selected for inclusion in this study. These individuals were discovered as part of a larger population-based study in the Old Order Amish. All subjects were given a complete eye examination with pupillary dilation. All of the study participants, aged 50 years and older, were asked to complete a brief questionnaire about present or past cigarette smoking history and the number of years of smoking. Simultaneously, 10 mL of blood were drawn from each patient by a certified phlebotomist. Digital stereo images of the macula, optic disc and macular OCT scans were obtained from all study participants using a Zeiss Cirrus OCT 4000 (Carl Zeiss Meditec, Dublin, CA, USA). The study was approved by the Institutional Review Boards of the University of Pennsylvania and University of Southern California and is consistent with the tenets set forth in the Declaration of Helsinki.

2.2. Genotyping

DNA was extracted from peripheral blood leukocytes using standard protocols (QiaAmp DNA Blood Mini kit, Cat#51106). We genotyped a total of 8 single-nucleotide polymorphisms for the following SNPs: SYN3 (rs5749482), LIPC (rs920915), ARMS2/HTRA1 (rs10490924), C3 (rs2230199), CFB (rs429608), CETP (rs3764261), CFI (rs10033900) and CFH (rs12038333) genes. The genotyping was done using TaqMan SNP Genotyping assays (Life Technologies, Grand Island, NY, USA) following the manufacturer’s instructions. Briefly, all PCR amplifications were performed with the following thermal cycling conditions: 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. PCR reactions were performed with TaqMan Genotyping Master Mix (Life Technologies, NY, USA) on a 7900HT Fast Real-Time PCR System (Life Technologies, NY, USA). All pre- and post-PCR plate readings were performed on a 7900HT Fast Real-Time PCR System, and the allele types were confirmed by the system’s software (7900HT Fast Real-Time PCR System SDS software version 2.3; Life Technologies).

2.3. Optical Coherence Tomography Acquisition

OCTs were obtained using the Cirrus OCT 4000 with a raster scan protocol (200 × 200). This acquisition protocol has been well established for gathering quantitative measurements of drusen area and drusen volume [28]. Scans of each eye were obtained after dilation and covered a retinal area of
6 × 6 mm, centered on the fovea. After acquisition, scans were immediately assessed by the operator for image quality (signal strength >7) and motion artifacts, and scans were repeated multiple times if necessary in order to obtain the best possible quality scan for subsequent analysis.

2.4. Quantification of Drusen and Areas of RPE Atrophy

Drusen and RPE analyses were performed using the FDA-cleared Cirrus Version 6.0 Advanced RPE Analysis algorithm. The reproducibility of this algorithm has been previously published [29–31], and we have demonstrated good agreement with manual segmentation of drusen by expert reading center graders [28,29]. The algorithm computes drusen area and volume by estimating the original RPE floor and subtracting it from the detected RPE surface (elevated by the drusen) [28]. The drusen area and volume are reported within a 3-mm diameter circle centered on the fovea, as well as within a surrounding perifoveal ring (outer ring diameter of 5 mm). Areas of RPE atrophy are also detected and quantified (within the 6 × 6-mm scanning square) automatically by the software based on identification of increased transmission of light into the choroid.

Two hundred sixty eight subjects were recruited for this study, but 51 subjects were excluded from subsequent quantitative analysis due to poor quality scans, missing scans or features of neovascular AMD, such as sub-retinal fluid, intra-retinal edema, sub-retinal tissue or serous pigment epithelial detachments in the OCT B-scans in at least one eye. One subject was excluded due to poor genotyping quality. Thus, 432 eyes of 216 consecutive subjects were included in this analysis. As one of our overall study objectives was to evaluate the correlation between eyes [32], only subjects with good quality scans for both eyes were considered for subsequent analysis.

2.5. Statistical Methods

To determine if there was an association among 3 genotypes of each SNP and drusen area/volume or area of RPE atrophy, the number of risk alleles for each genotype was counted as either 0, 1 or 2, and genotype association with each OCT measure from an eye was evaluated using tests of linear trend from generalized linear models with inter-eye correlation accounted for using generalized estimating equations (GEE). For the SNP of SYN3, only two genotypes (GG and CG) were observed in the study participants, and the comparison between two genotypes were performed using analysis of variance, with inter-eye correlation accounted for using GEE. The effect for each risk allele on the drusen area/volume was estimated based on the slope of generalized linear regression models. These evaluations were evaluated using univariate analysis (without adjustment of risk factors of AMD) and multivariate analysis (with adjustment of age, gender and smoking status). To account for multiple comparisons from multiple SNPs and multiple OCT measurements, we adjusted $p$-values using the global false discovery rate [33]. All analyses were performed in SAS V9.2 (SAS Institute Inc., Cary, NC, USA) software; $p < 0.05$ was considered to be statistically significant.

3. Results

A total of 268 subjects were recruited for our study; 51 subjects were excluded either due to poor quality scans or features of neovascular AMD on OCT in at least one eye, and one additional subject was removed due
to poor quality genotypes. Thus, 432 eyes of 216 subjects were included for analysis. SNP genotyping for eight SNPs was completed on all 216 subjects. Our sample included a total of 122 women and 94 men with a mean age ($\pm$ standard deviation) of 73 $\pm$ 6.6 years (range: 50–89). The majority of the subjects was between 70 and 79 years of age (56.1%), and 50 (23.2%) had a history of smoking (Table 1).

Table 1. Characteristics of study subjects ($N = 216$).

| Age (years) |          |
|-------------|----------|
| 50–59       | 5 (2.3%) |
| 60–69       | 57 (26.4%)|
| 70–79       | 120 (55.6%)|
| $\geq$80    | 32 (14.8%)|
| Unknown     | 2 (0.9%) |
| Mean (standard deviation) | 70.3 (6.63) |

| Gender       |          |
|--------------|----------|
| Female       | 122 (56.5%)|
| Male         | 94 (43.5%)|

| Ever Smoked |          |
|-------------|----------|
| Yes         | 50 (23.2%)|
| No          | 157 (72.7%)|
| Unknown     | 9 (4.2%) |

Table 2 shows the comparison of drusen areas/volumes and areas of RPE atrophy with genotype. In univariate analysis, significant associations of the drusen area in the perifoveal ring (PR, $p = 0.006$) and drusen area in the central circle (CC, $p = 0.02$) were observed for the risk allele GG in SYN3 (SNP, rs5749482). The drusen volume CC ($p = 0.02$) and drusen volume PR ($p = 0.03$) were also significantly associated with SYN3. The association of the area of RPE atrophy with SYN3 showed a trend, but did not reach statistical significance ($p = 0.07$). The associations between drusen area PR ($p = 0.03$) and drusen volume CC ($p = 0.04$) with SYN3 remained even after adjustment for age, gender and smoking status. However, these associations become non-significant after multiple comparison adjustment for the total of 40 tests in this study. It is interesting to observe that the majority of the 216 subjects have the SYN3 GG risk alleles (91%). This high percentage of GG risk alleles could be attributed to interbreeding and being isolated in terms of lifestyle and culture. The homozygous CC genotype was not observed in our study population.

In univariate analysis, we observed a significant association of the CFH risk allele GG for SNP, rs12038333, with drusen area CC ($p = 0.007$), drusen area PR ($p = 0.002$), drusen volume CC ($p = 0.049$), drusen volume PR ($p = 0.002$) and area of RPE atrophy ($p = 0.003$); and these associations remained after adjustment for age, gender and smoking status (Table 2). Even after multiple comparison adjustment, the association between CFH with drusen area PR and drusen volume CC ($p = 0.04$, respectively, Table 2) remained significant. Our results indicate that SNPs in the CFH and SYN3 genes are important influences for drusen size and volume in the macula and perifoveal region, a hallmark of AMD.

The drusen area, drusen volume and regions of RPE atrophy did not show any significant association with SNPs in the other genes that were tested (Table 2).
**Table 2.** Genotypic associations with optical coherence tomography (OCT) drusen area, drusen volume and area of retinal pigment epithelium (RPE) atrophy from univariate analysis and multivariate analysis § (216 subjects, 432 eyes).

| SNP                        | Genotype | N  | Drusen Area in mm²:       | Drusen Volume in mm³:       | Area of RPE Atrophy in mm²:       |
|---------------------------|----------|----|--------------------------|----------------------------|-----------------------------------|
|                           |          |    | Central Circle | Perifoveal Ring | Central Circle | Perifoveal Ring |                          |
|                           |          |    |              |                |              |                |                          |
| normal/(risk) SYN3 C/(G)  |          |    |              |                |              |                |                          |
| rs5749482                 |          |    |              |                |              |                |                          |
| GG                        | 198      | 0.23 (0.05) | 0.18 (0.04) | 0.02 (0.01) | 0.008 (0.002) | 0.50 (0.11) |
| CG                        | 18       | 0.06 (0.04) | 0.03 (0.02) | 0.002 (0.002) | 0.002 (0.001) | 0.19 (0.11) |
| CC                        | 0        | -                           | -                           | -                           | -                           |                          |
| Univariate P *            |          | 0.02                          | 0.006                         | 0.02                          | 0.03                          | 0.07                          |
| Adjusted Slope (SE) †     |          | 0.11 (0.06)                   | 0.09 (0.04)                   | 0.01 (0.005)                  | 0.004 (0.002)                 | 0.09 (0.16)                  |
| Multivariate P †          |          | 0.08                          | 0.03                          | 0.04                          | 0.09                          | 0.58                          |
| Multiple comparison adjusted P by global FDR ‡ |          | 0.36                          | 0.26                          | 0.26                          | 0.36                          | 0.84                          |
| (risk)/normal LIPC (C)/G  |          |    |              |                |              |                |                          |
| rs920915                  |          |    |              |                |              |                |                          |
| CC                        | 58       | 0.26 (0.08) | 0.24 (0.08) | 0.02 (0.01) | 0.01 (0.01) | 0.78 (0.29) |
| CG                        | 122      | 0.22 (0.07) | 0.15 (0.04) | 0.02 (0.01) | 0.007 (0.002) | 0.40 (0.11) |
| GG                        | 37       | 0.11 (0.03) | 0.09 (0.04) | 0.004 (0.001) | 0.004 (0.002) | 0.22 (0.09) |
| Univariate Linear Trend P * |          | 0.16                          | 0.14                          | 0.28                          | 0.19                          | 0.08                          |
| Adjusted Slope (SE) †     |          | 0.06 (0.05)                   | 0.07 (0.04)                   | 0.005 (0.004)                 | 0.004 (0.003)                 | 0.21 (0.13)                  |
| Multivariate Linear Trend P † |          | 0.16                          | 0.14                          | 0.26                          | 0.20                          | 0.12                          |
| Multiple comparison adjusted P by global FDR ‡ |          | 0.49                          | 0.47                          | 0.69                          | 0.57                          | 0.44                          |
| (risk)/normal ARMS2 G/(T) |          |    |              |                |              |                |                          |
| rs10490924                |          |    |              |                |              |                |                          |
| TT                        | 20       | 0.48 (0.14) | 0.39 (0.10) | 0.02 (0.01) | 0.01 (0.00) | 1.48 (0.55) |
| GT                        | 81       | 0.15 (0.05) | 0.13 (0.05) | 0.008 (0.003) | 0.005 (0.002) | 0.45 (0.18) |
| GG                        | 114      | 0.21 (0.07) | 0.15 (0.05) | 0.02 (0.01) | 0.008 (0.003) | 0.31 (0.10) |
| Univariate Linear Trend P * |          | 0.40                          | 0.20                          | 0.48                          | 0.77                          | 0.045                          |
| Adjusted Slope (SE) †     |          | 0.04 (0.07)                   | 0.05 (0.05)                   | −0.01 (0.01)                  | −0.0003 (0.003)               | 0.37 (0.18)                  |
| Multivariate Linear Trend P † |          | 0.59                          | 0.41                          | 0.41                          | 0.92                          | 0.051                          |
| Multiple comparison adjusted P by global FDR ‡ |          | 0.84                          | 0.77                          | 0.77                          | 0.95                          | 0.26                          |
### Table 2. Cont.

| SNP                        | Genotype | N | Drusen Area in mm²: Mean (SE) | Drusen Volume in mm³: Mean (SE) | Area of RPE Atrophy in mm²: Mean (SE) |
|----------------------------|----------|---|-------------------------------|-------------------------------|--------------------------------------|
|                            |          |   | Central Circle                | Perifoveal Ring               | Central Circle                      | Perifoveal Ring                      |
| (risk)/normal C3 (C)/G     | CC       | 1 | 0.20 (0.00)                   | 0.05 (0.00)                   | 0.008 (0.000)                       | 0.002 (0.000)                       |
|                            | CG       | 22| 0.30 (0.13)                   | 0.20 (0.10)                   | 0.01 (0.01)                         | 0.007 (0.004)                       |
|                            | GG       | 194| 0.20 (0.05)                   | 0.16 (0.04)                   | 0.01 (0.01)                         | 0.008 (0.002)                       |
| Univariate Linear Trend P *|          |   | 0.51                         | 0.80                          | 0.82                                | 0.78                                |
| Adjusted Slope (SE) †      |          |   | −0.001 (0.01)                 | −0.002 (0.004)                | 0.27 (0.37)                         |
| Multivariate Linear Trend P †|         |   | 0.50                         | 0.91                          | 0.91                                | 0.66                                |
| Multiple comparison adjusted P by global FDR ‡ |         |   | 0.77                         | 0.95                          | 0.95                                | 0.88                                |
| normal/(risk) CFB A/(G)    | GG       | 196| 0.21 (0.04)                   | 0.17 (0.04)                   | 0.01 (0.00)                         | 0.008 (0.002)                       |
|                            | AG       | 19| 0.23 (0.20)                   | 0.12 (0.10)                   | 0.03 (0.02)                         | 0.008 (0.008)                       |
|                            | AA       | 2 | 0.000 (0.000)                 | 0.02 (0.02)                   | 0.000 (0.000)                       | 0.001 (0.001)                       |
| Univariate Linear Trend P *|          |   | 0.90                         | 0.43                          | 0.73                                | 0.88                                |
| Adjusted Slope (SE) †      |          |   | −0.01 (0.02)                  | 0.001 (0.01)                  | 0.13 (0.16)                         |
| Multivariate Linear Trend P †|         |   | 0.90                         | 0.47                          | 0.75                                | 0.89                                |
| Multiple comparison adjusted P by global FDR ‡ |         |   | 0.95                         | 0.77                          | 0.94                                | 0.95                                |
| (risk)/normal CETP (A)/C   | AA       | 21| 0.10 (0.06)                   | 0.09 (0.05)                   | 0.003 (0.002)                       | 0.003 (0.002)                       |
|                            | AC       | 97| 0.28 (0.07)                   | 0.20 (0.06)                   | 0.02 (0.01)                         | 0.01 (0.00)                         |
|                            | CC       | 96| 0.17 (0.06)                   | 0.16 (0.05)                   | 0.01 (0.01)                         | 0.006 (0.002)                       |
| Univariate Linear Trend P *|          |   | 0.71                         | 0.91                          | 0.96                                | 0.83                                |
| Adjusted Slope (SE) †      |          |   | 0.03 (0.05)                   | 0.002 (0.04)                  | 0.001 (0.01)                        | 0.001 (0.002)                       |
| Multivariate Linear Trend P †|         |   | 0.62                         | 0.97                          | 0.93                                | 0.72                                |
| Multiple comparison adjusted P by global FDR ‡ |         |   | 0.86                         | 0.97                          | 0.95                                | 0.93                                |
Table 2. Cont.

| SNP | Genotype | N   | Drusen Area in mm²: Mean (SE) | Drusen Volume in mm³: Mean (SE) | Area of RPE Atrophy in mm²: Mean (SE) |
|-----|----------|-----|-------------------------------|---------------------------------|-------------------------------------|
|     |          |     | Central Circle | Perifoveal Ring | Central Circle | Perifoveal Ring | Central Circle | Perifoveal Ring |
| rs10033900 |          |     |                |                   |                |                   |                |                   |
| normal/(risk) |          |     |                |                   |                |                   |                |                   |
| CFI C/(T)     | TT      | 17  | 0.14 (0.09)    | 0.06 (0.02)       | 0.01 (0.01)     | 0.002 (0.001)     | 0.32 (0.25)    |
|              | CT      | 115 | 0.19 (0.04)    | 0.18 (0.05)       | 0.010 (0.004)   | 0.008 (0.003)     | 0.55 (0.15)    |
|              | CC      | 85  | 0.26 (0.09)    | 0.17 (0.06)       | 0.02 (0.01)     | 0.009 (0.003)     | 0.39 (0.16)    |
| rs12038333   | GG      | 49  | 0.30 (0.08)    | 0.29 (0.08)       | 0.01 (0.00)     | 0.01 (0.00)       | 1.15 (0.32)    |
|              | AG      | 99  | 0.26 (0.08)    | 0.19 (0.06)       | 0.02 (0.01)     | 0.01 (0.00)       | 0.36 (0.13)    |
|              | AA      | 69  | 0.08 (0.04)    | 0.04 (0.02)       | 0.005 (0.003)   | 0.002 (0.001)     | 0.14 (0.07)    |

* Adjusted by age, gender and smoking status; * From univariate analysis (without adjustment by any other risk factors of age-related macular degeneration (AMD)) for testing whether OCT measures were associated with the number of risk alleles; † From multivariate analysis (with adjustment by age, gender and smoking status) for testing whether OCT measures were associated with the number of risk alleles; ‡ Adjusted using global FDR (false discovery rate) for multiple comparisons from eight SNPs and five OCT measurements (i.e., adjustment for a total of 40 tests) for p-values from multivariate analysis.
4. Discussion

We have examined the association of eight known AMD genetic variants with drusen phenotypes assessed by the Cirrus OCT. There was a strong association between drusen area, volume and RPE atrophy in the macula with risk alleles in \textit{CFH} (rs12038333) and \textit{SYN3} (rs5749482). These eight SNPs have been reported to be highly associated with AMD [34].

The role of genetic variants in drusen accumulation and early AMD has received little attention [35–37]. HDL pathway genes are reported to be associated with the early stages of AMD, whereas \textit{ARMS2/HTRA1} and genes in the complement pathway are associated with more advanced stages [35]. \textit{CFH}, \textit{ARMS2/HTRA1} and \textit{C3} genes have been reported to increase the risk of progression from intermediate drusen to large drusen and from large drusen to geographic atrophy and neovascularization. The T allele of rs1883025 in \textit{ABCA1} is associated with a decreased risk of intermediate drusen, large drusen, geographic atrophy (GA) and neovascularization [35], whereas the C allele of \textit{COL8A1} is protective of the transition from intermediate to large drusen [38].

Significant association of drusen progression with \textit{CFH} has been reported in Age-Related Eye Disease Study (AREDS) and familial AMD cohorts [39]. Smoking is strongly associated with a 2.5- to 4.5-fold increased risk for late AMD [40], and its risk is known to increase 6–14-fold with the presence of the CFH polymorphism [41]. The CFH Y402H is reported to act synergistically with smoking to increase the risk of wet AMD [42]. We have observed a strong association of the CFH SNP rs1203833 with macular drusen area and volume in our Amish AMD cohort, thus supporting the hypothesis that this variant is relevant to drusen formation.

Variants in the \textit{SYN3} gene are reported to influence susceptibility to AMD [43]. The \textit{SYN3} gene is a member of the Synapsin gene family and is known to play a role in synaptogenesis and in the modulation of neurotransmitter release. The associated \textit{SYN3} SNP (rs5749482) with AMD is located in the \textit{SYN3} intron 6. This SNP could be influencing the expression of \textit{SYN3} or a nearby gene, \textit{TIMP3}, which is located within the same intron. Further screening of Amish cohorts with SNP, rs9621532, in \textit{TIMP3} could elucidate its role in AMD [43–45]. To our knowledge, this is the first report to demonstrate an association of \textit{SYN3} with quantitative macular drusen burden in AMD. Additional SNPs for the \textit{SYN3} gene need to be screened to further understand the role of this gene in influencing drusen formation.

Apart from \textit{CFH} and \textit{SYN3}, the other genotyped genes, \textit{ARMS2}, \textit{C3}, \textit{CFB}, \textit{LIPC}, \textit{CETP} and \textit{CFI} genes, were not associated with our drusen phenotypes. This could be due to insufficient power in our study to detect small effects. Additional studies of these SNPs in different populations are needed to establish haplotypes for drusen burden in AMD. Our study was limited to subjects older than 50 years. Therefore, we cannot determine the effect of these SNPs on the development of drusen at a younger age. Although analysis of the Amish cohort has identified strong associations between \textit{CFH}, \textit{SYN3} and drusen area and volume, both false positive and false negatives may be present due to the overall small sample size. The stringency of our inclusion criteria, the use of a validated FDA-cleared OCT algorithm for drusen measurements and our reproducible genotyping are the strengths of our study. Our results also provide a foundation to further evaluate other SNPs in the known AMD genes for association with drusen phenotypes.

Color fundus photographs (CFPs) offer complementary information to SD-OCT [46]. Both methods play an important role in assessing drusen and RPE atrophy in patients with non-exudative AMD [47,48].
However, issues with the CFPs’ reproducibility due to fundus pigmentation variability and drusen appearance and media opacity negatively impacting photograph quality make SD-OCT a promising alternative for imaging drusen. SD-OCT provides information regarding drusen ultrastructure in vivo and quantifies the thickness of the drusen, as well as the photoreceptor layer above the drusen [49–51]. Future genetic correlation studies, however, may consider incorporating and integrating phenotypic information derived from multiple imaging modalities (e.g., color photographs, fundus autofluorescence, and OCT) to yield a more precise description of the disease phenotype.

5. Conclusions

Our data suggest that CFH and SYN3 risk alleles play a role in determining the drusen phenotype in the Amish population. This approach of stratifying drusen phenotypes by genotype has the potential to separate AMD patients into homogenous groups for preventive and therapeutic studies. Of course, more SNPs will need to be evaluated to deliver such a genotype-phenotype classification.

Acknowledgments

This work is supported in part by NIH grant RO1 EY023164 to Stambolian and Sadda.

Author Contributions

Venkata Ramana Murthy Chavali, Bruno Diniz and Jiayan Huang wrote the initial draft based on initial discussions and suggestions from Dwight Stambolian, Gui-Shuang Ying and SriniVas R. Sadda. Gui-Shuang Ying and Jiayan Huang contributed the Tables and data analysis. Dwight Stambolian, SriniVas R. Sadda and Gui-Shuang Ying contributed to the critical evaluation and proof reading of the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related eye disease study report number 3. *Ophthalmology* 2000, 107, 2224–2232.
2. Friedman, D.S.; O’Colmain, B.J.; Munoz, B.; Tomany, S.C.; McCarty, C.; de Jong, P.T.; Nemesure, B.; Mitchell, P.; Kempen, J.; et al. Prevalence of age-related macular degeneration in the United States. *Arch. Ophthalmol.* 2004, 122, 564–572.
3. Fine, S.L.; Berger, J.W.; Maguire, M.G.; Ho, A.C. Age-related macular degeneration. *N. Engl. J. Med.* 2000, 342, 483–492.
4. Hageman, G.S.; Luthert, P.J.; Victor Chong, N.H.; Johnson, L.V.; Anderson, D.H.; Mullins, R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-bruch’s membrane interface in aging and age-related macular degeneration. *Prog. Retin. Eye Res.* **2001,*** 20, 705–732.

5. Lutty, G.; Grunwald, J.; Majji, A.B.; Uyama, M.; Yoneya, S. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. *Mol. Vis.* **1999,*** 5, 35.

6. Wang, J.J.; Foran, S.; Smith, W.; Mitchell, P. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: The blue mountains eye study cohort. *Arch. Ophthalmol.* **2003,*** 121, 658–663.

7. Klein, R.J.; Zeiss, C.; Chew, E.Y.; Tsai, J.Y.; Sackler, R.S.; Haynes, C.; Henning, A.K.; SanGiovanni, J.P.; Mane, S.M.; Mayne, S.T.; *et al.* Complement factor H polymorphism in age-related macular degeneration. *Science* **2005,*** 308, 385–389.

8. Edwards, A.O.; Ritter, R., III; Abel, K.J.; Manning, A.; Panhuysen, C.; Farrer, L.A. Complement factor H polymorphism and age-related macular degeneration. *Science* **2005,*** 308, 421–424.

9. Hageman, G.S.; Anderson, D.H.; Johnson, L.V.; *et al.* A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. *Proc. Natl. Acad. Sci. USA* **2005,*** 102, 7227–7232.

10. Hughes, A.E.; Orr, N.; Esfandiary, H.; Diaz-Torres, M.; Goodship, T.; Chakravarthy, U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. *Nat. Genet.* **2006,*** 38, 1173–1177.

11. Gold, B.; Merriam, J.E.; Zernant, J.; Hancox, L.S.; Taiber, A.J.; Gehrs, K.; Cramer, K.; Neel, J.; Bergeron, J.; Barile, G.R.; *et al.* Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. *Nat. Genet.* **2006,*** 38, 458–462.

12. Spencer, K.L.; Hauser, M.A.; Olson, L.M.; Schmidt, S.; Scott, W.K.; Gallins, P.; Agarwal, A.; Postel, E.A.; Pericak-Vance, M.A.; Haines, J.L. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. *Hum. Mol. Genet.* **2007,*** 16, 1986–1992.

13. Fagerness, J.A.; Maller, J.B.; Neale, B.M.; Reynolds, R.C.; Daly, M.J.; Seddon, J.M. Variation near complement factor I is associated with risk of advanced AMD. *Eur. J. Hum. Genet.* **2009,*** 17, 100–104.

14. Yates, J.R.; Sepp, T.; Matharu, B.K.; Khan, J.C.; Thurlby, D.A.; Shahid, H.; Clayton, D.G.; Hayward, C.; Morgan, J.; Wright, A.F.; *et al.* Complement C3 variant and the risk of age-related macular degeneration. *N. Engl. J. Med.* **2007,*** 357, 553–561.

15. Maller, J.; George, S.; Purcell, S.; Fagerness, J.; Althusher, D.; Daly, M.J.; Seddon, J.M. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. *Nat. Genet.* **2006,*** 38, 1055–1059.

16. Jakobsdottir, J.; Conley, Y.P.; Weeks, D.E.; Mah, T.S.; Ferrell, R.E.; Gorin, M.B. Susceptibility genes for age-related maculopathy on chromosome 10q26. *Am. J. Hum. Genet.* **2005,*** 77, 389–407.

17. Rivera, A.; Fisher, S.A.; Fritsche, L.G.; Keilhauer, C.N.; Lichtner, P.; Meitinger, T.; Weber, B.H. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. *Hum. Mol. Genet.* **2005,*** 14, 3227–3236.
18. Yang, Z.; Camp, N.J.; Sun, H.; Tong, Z.; Gibbs, D.; Cameron, D.J.; Chen, H.; Zhao, Y.; Pearson, E.; Li, X.; et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. *Science* 2006, 314, 992–993.

19. Kanda, A.; Chen, W.; Othman, M.; Branham, K.E.; Brooks, M.; Khanna, R.; He, S.; Lyons, R.; Abecasis, G.R.; Swaroop, A. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. *Proc. Natl. Acad. Sci. USA* 2007, 104, 16227–16232.

20. Hasham, S.N.; Pillarisetti, S. Vascular lipases, inflammation and atherosclerosis. *Clin. Chim. Acta* 2006, 372, 179–183.

21. Kathiresan, S.; Willer, C.J.; Peloso, G.M.; Demissie, S.; Musunuru, K.; Schadt, E.E.; Kaplan, L.; Bennett, D.; Li, Y.; Tanaka, T.; et al. Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat. Genet.* 2009, 41, 56–65.

22. Keebler, M.E.; Sanders, C.L.; Surti, A.; Guiducci, C.; Burtt, N.P.; Kathiresan, S. Association of blood lipids with common DNA sequence variants at 19 genetic loci in the multiethnic united states national health and nutrition examination survey III. *Circ. Cardiovasc. Genet.* 2009, 2, 238–243.

23. Davis, M.D.; Gangnon, R.E.; Lee, L.Y.; Hubbard, L.D.; Klein, B.E.; Klein, R.; Ferris, F.L.; Bressler, S.B.; Milton, R.C.; Age-Related Eye Disease Study Group. The age-related eye disease study severity scale for age-related macular degeneration: AREDS report no. 17. *Arch. Ophthalmol.* 2005, 123, 1484–1498.

24. Klein, R.; Klein, B.E.; Jensen, S.C.; Meuer, S.M. The five-year incidence and progression of age-related maculopathy: The beaver dam eye study. *Ophthalmology* 1997, 104, 7–21.

25. Shin, D.S.; Javornik, N.B.; Berger, J.W. Computer-assisted, interactive fundus image processing for macular drusen quantitation. *Ophthalmology* 1999, 106, 1119–1125.

26. Zheng, Y.J.; Vanderbeek, B.; Daniel, E.; Stambolian, D.; Maguire, M.; Brainard, D.; Gee, J. An automated drusen detection system for classifying age-related macular degeneration with color fundus photographs. In Proceedings of the 2013 IEEE 10th International Symposium on Biomedical Imaging, San Francisco, CA, USA, 2013; pp. 1448–1451.

27. Srinivasan, V.J.; Wojtkowski, M.; Witkin, A.J.; Duker, J.S.; Ko, T.H.; Carvalho, M.; Schuman, J.S.; Kowalczyk, A.; Fujimoto, J.G. High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. *Ophthalmology* 2006, 113, doi:10.1016/j.ophtha.2006.05.046.

28. Gregori, G.; Wang, F.; Rosenfeld, P.J.; Yehoshua, Z.; Gregori, N.Z.; Lujan, B.J.; Puliafito, C.A.; Feuer, W.J. Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration. *Ophthalmology* 2011, 118, 1373–1379.

29. Nittala, M.G.; Ruiz-Garcia, H.; Sadda, S.R. Accuracy and reproducibility of automated drusen segmentation in eyes with non-neovascular age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.* 2012, 53, 8319–8324.

30. Yehoshua, Z.; Gregori, G.; Sadda, S.R.; Penha, F.M.; Goldhardt, R.; Nittala, M.G.; Konduru, R.K.; Feuer, W.J.; Gupta, P.; Li, Y.; et al. Comparison of drusen area detected by spectral domain optical coherence tomography and color fundus imaging. *Investig. Ophthalmol. Vis. Sci.* 2013, 54, 2429–2434.
31. Yehoshua, Z.; Rosenfeld, P.J.; Gregori, G.; Feuer, W.J.; Falcao, M.; Lujan, B.J.; Puliafito, C. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. *Ophthalmology* 2011, 118, 679–686.

32. Diniz, B.; Rodger, D.C.; Chavali, V.; MacKay, T.; Lee, S.Y.; Stambolian, D.; Sadda, S.V. Drusen and RPE atrophy automated quantification by optical coherence tomography in an elderly population. *Eye (Lond)* 2014, doi:10.1038/eye.2014.260.

33. Lederman, M.; Weiss, A.; Chowers, I. Association of neovascular age-related macular degeneration with specific gene expression patterns in peripheral white blood cells. *Investig. Ophthalmol. Vis. Sci.* 2010, 51, 53–58.

34. Fritsche, L.G.; Chen, W.; Schu, M.; Yaspan, B.L.; Yu, Y.; Thorleifsson G.; Zack, D.J.; Arakawa, S.; Cipriani, V.; Ripke, S.; *et al.* Seven new loci associated with age-related macular degeneration. *Nat. Genet.* 2013, 45, 433–439.

35. Yu, Y.; Reynolds, R.; Fagerness, J.; Rosner, B.; Daly, M.J.; Seddon, J.M. Association of variants in the *LIPC* and *ABCA1* genes with intermediate and large drusen and advanced age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.* 2011, 52, 4663–4670.

36. Boon, C.J.; Klevering, B.J.; Hoyng, C.B.; Zonneveld-Vrielings, M.N.; Nabuurs, S.B.; Blokland, E.; Cremers, F.P.; den Hollander, A.I. Basal laminar drusen caused by compound heterozygous variants in the *CFH* gene. *Am. J. Hum. Genet.* 2008, 82, 516–523.

37. Munch, I.C.; Ek, J.; Kessel, L.; Sander B.; Almind, G.J.; Brondum-Nielsen, K.; Linneberg, A.; Larsen, M. Small, hard macular drusen and peripheral drusen: Associations with AMD genotypes in the Inter99 eye study. *Investig. Ophthalmol. Vis. Sci.* 2010, 51, 2317–2321.

38. Yu, Y.; Reynolds, R.; Rosner, B.; Daly, M.J.; Seddon, J.M. Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate markov models. *Investig. Ophthalmol. Vis. Sci.* 2012, 53, 1548–1556.

39. Francis, P.J.; Schultz, D.W.; Hamon, S.; Ott, J.; Welleber, R.G.; Klein, M.L. Haplotypes in the complement factor H (*CFH*) gene: Associations with drusen and advanced age-related macular degeneration. *PLoS One* 2007, 2, e1197.

40. Thornton, J.; Edwards, R.; Mitchell, P.; Harrison, R.A.; Buchan, I.; Kelly, S.P. Smoking and age-related macular degeneration: A review of association. *Eye (Lond)* 2005, 19, 935–944.

41. Tan, J.S.; Mitchell, P.; Kifley, A.; Flood, V.; Smith, W.; Wang, J.J. Smoking and the long-term incidence of age-related macular degeneration: The blue mountains eye study. *Arch. Ophthalmol.* 2007, 125, 1089–1095.

42. Clark, S.J.; Perveen, R.; Hakobyan, S.; Morgan B.P.; Sim, R.B.; Bishop, P.N.; Day, A.J. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to bruch’s membrane in human retina. *J. Biol. Chem.* 2010, 285, 30192–30202.

43. Chen, W.; Stambolian, D.; Edwards, A.O.; Branham, K.E.; Othman, M.; Jakobsdottir, J.; Tosakulwong, N.; Pericak-Vance, M.A.; Campochiaro, P.A.; Klein, M.L.; *et al.* Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. *Proc. Natl. Acad. Sci. USA* 2010, 107, 7401–7406.
44. Ardeljan, D.; Meyerle, C.B.; Agron, E.; Wang, J.J.; Mitchell, P.; Chew, E.Y.; Zhao, J.; Maminishkis, A.; Chan, C.C.; Tuo, J. Influence of TIMP3/SYN3 polymorphisms on the phenotypic presentation of age-related macular degeneration. *Eur. J. Hum. Genet.* 2013, 21, 1152–1157.

45. Kamei, M.; Hollyfield, J.G. TIMP-3 in bruch’s membrane: Changes during aging and in age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.* 1999, 40, 2367–2375.

46. Bartlett, H.; Eperjesi, F. Use of fundus imaging in quantification of age-related macular change. *Surv. Ophthalmol.* 2007, 52, 655–671.

47. Yehoshua, Z.; Rosenfeld, P.J.; Gregori, G.; Penha, F. Spectral domain optical coherence tomography imaging of dry age-related macular degeneration. *Ophthalmic Surg. Lasers Imaging* 2010, 41, doi:10.3928/15428877-20101031-19.

48. Jain, N.; Farsiu, S.; Khanifar, A.A.; Bearelly, S.; Smith, R.T.; Izatt, J.A.; Toth, C.A. Quantitative comparison of drusen segmented on SD-OCT versus drusen delineated on color fundus photographs. *Investig. Ophthalmol. Vis. Sci.* 2010, 51, 4875–4883.

49. Khanifar, A.A.; Koreishi, A.F.; Izatt, J.A.; Toth, C.A. Drusen ultrastructure imaging with spectral domain optical coherence tomography in age-related macular degeneration. *Ophthalmology* 2008, 115, 1883–1890.

50. Schuman, S.G.; Koreishi, A.F.; Farsiu, S.; Jung, S.H.; Izatt, J.A.; Toth, C.A. Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. *Ophthalmology* 2009, 116, doi:10.1016/j.ophtha.2008.10.006.

51. Yi, K.; Mujat, M.; Park, B.H.; Sun, W.; Miller, J.W.; Seddon, J.M.; Young, L.H.; de Boer, J.F.; Chen, T.C. Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in non-neovascular age-related macular degeneration. *Br. J. Ophthalmol.* 2009, 93, 176–181.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).